相关产品推荐更多 >

Integrin alpha V Recombinant Rabbit mAb (S-1798-27)【整合素αV重组兔单克隆抗体(S - 1798 - 27)】
¥600
Rabbit anti-Collagen 7α 1 Polyclonal Antibody【兔抗胶原蛋白7α1多克隆抗体】- abs148992
¥1500
Alexa Fluor® 488 Mouse Anti-Human CD38 Antibody (S-R507-3)【Alexa Fluor® 488 小鼠抗人CD38抗体(S-R507-3)】
¥650
EpCAM/CD326 Recombinant Rabbit mAb (S-1009-76)【上皮细胞黏附分子(EpCAM)/CD326 重组兔单克隆抗体(S - 1009 - 76)】
¥600
Rabbit anti-MUC15 Polyclonal Antibody(C-term)【兔抗MUC15多克隆抗体(C端)】
¥1500
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
Anti-HEL Human IgG1-λ1 Isotype Control Monoclonal mAb
- 抗体英文名:
Anti-HEL Human IgG1-λ1 Isotype Control Monoclonal Antibody
- 靶点:
见优宁维官网
- 浓度:
5-20mg/ml
- 应用范围:
见优宁维官网
- 宿主:
CHO
- 适应物种:
见优宁维官网
- 保质期:
见优宁维官网
- 抗原来源:
见优宁维官网
- 级别:
优级
- 库存:
999
- 供应商:
Absin
- 标记物:
Unlabeled
- 克隆性:
见优宁维官网
- 保存条件:
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.
- 免疫原:
见优宁维官网
- 规格:
5mg/1mg/25mg
| 规格: | 5mg | 产品价格: | ¥6700.0 |
|---|---|---|---|
| 规格: | 1mg | 产品价格: | ¥1500.0 |
| 规格: | 25mg | 产品价格: | ¥17500.0 |
别名:抗HEL人IgG1-λ1同型对照单克隆抗体
免疫原:见优宁维官网
应用:见优宁维官网
保持条件:2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.
使用方法:Functional/Block/Neutralize
标记:Unlabeled
宿主:CHO
反应种属:见优宁维官网
克隆性:见优宁维官网
产品描述:见优宁维官网
爱必信品牌介绍:

更多详情请了解优宁维网站》》
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Isotype-specific immunostaining with mouse primary antibodies on mouse tissue
on mouse tissue are of IgG1 isotype. Detailed explanation of this method can be found in: Cattoretti G, Qing Fei. Application of the Antigen Retrieval Technique in experimental Pathology: from human to mouse
Rapid Isotyping of Mouse Monoclonal Antibodies
, isotyping is useful to control lot to lot consistency, detect contamination by another antibody, and identify hybridoma switch variants (see Notes 2 –8 for further comment on applications). Table 1 Isotype-Dependent Properties of Monoclonal
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料





